Aequus’ GlycoPolymer technology allows scientists to create novel biopharmaceuticals that require less frequent injections (i.e., monthly rather than daily) due to their improved pharmacokinetic properties.
The GlycoPolymer technology approach genetically ligates an external polypeptide domain to a biologically active protein or peptide, which results in additional N-linked glycosylation during manufacture. The presence of additional N-linked glycosylation has been demonstrated to have a beneficial effect on a protein's plasma half-life. This modular approach provides a more technically straightforward and predictable approach to extending the plasma half-life of biologically active proteins and peptides compared to the previously utilized method of engineering internal glycosylation sites.
Find out how we can collaborate to efficiently develop your therapeutic protein drug candidate utilizing Aequus' GlycoPolymer technology